Abacavir (Ziagen)

Published January 23, 2001; Updated June 2018
Susa Coffey, MD
Selected References
16. Severe Hypersensitivity Reactions following Reintroduction with ZIAGEN (abacavir sulfate) Products. FDA MedWatch letter, Glaxo Wellcome, updated 7/27/2000.
17. Loeliger  AE, Steel  H, McGuirk  S, Powell  WS, Hetherington  SV.
The abacavir hypersensitivity reaction and interruptions in therapy. AIDS. 2001 Jul;15(10):1325-6
[PubMed ID: 11426085]
No abstract
18. Berenguer  J, Padilla  B, Estrada  V, Martín  C, Domingo  P, Kindelán  JM, Ruiz-Guiardin  JM.
Safety of abacavir therapy after temporary interruptions in patients without hypersensitivity reactions to the drug. AIDS. 2002 Jun;16(9):1299-301
[PubMed ID: 12045501]
No abstract